Carboplatin and paclitaxol (Taxol) as an induction regimen for patients with biopsy-proven stage IIIA N2 non-small cell lung cancer: An EORTC phase II study (EORTC 08958)

European Journal of Cancer

Volumn 39, Issue 10, 2003, Pages 1416-1422

  O'Brien, M E R ^a   Splinter, T ^b   Smit, E F ^c   Biesma, B ^d   Krzakowski, M ^e   Tjan Heijnen, V C G ^f   Van Bochove, A ^g   Stigt, J ^h   Smid Geirnaerdt, M J A ⁱ   Debruyne, C ^j   Legrand, C ^j   Giaccone, G ^c  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^d JEROEN BOSCH HOSPITAL   (Netherlands)

^e INSTITUTE OF ONCOLOGY   (Poland)

^f RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^g ZAANS MEDICAL CENTER   (Netherlands)

^h Sophia Hospital   (Netherlands)

ⁱ Stichting Oosterschelde Ziekenhuizen   (Netherlands)

^j EORTC DATA CENTER   (Belgium)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CIMETIDINE; DEXAMETHASONE; DIPHENHYDRAMINE; PACLITAXEL;

ADULT; ALOPECIA; ANEMIA; ANOREXIA; AREA UNDER THE CURVE; ARTHRALGIA; CANCER MORTALITY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; CONCENTRATION (PARAMETERS); CONFERENCE PAPER; CONFIDENCE INTERVAL; DISEASE SEVERITY; DOSE CALCULATION; DRUG HYPERSENSITIVITY; DRUG INFUSION; DRUG RESPONSE; DRUG TOLERABILITY; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; HUMAN TISSUE; INFORMED CONSENT; LETHARGY; LEUKOPENIA; LUNG NON SMALL CELL CANCER; LUNG RESECTION; MAJOR CLINICAL STUDY; MALAISE; MALE; MEDIASTINUM; MYALGIA; NAUSEA; NEUROTOXICITY; NEUTROPENIA; PRIORITY JOURNAL; RASH; SKIN TOXICITY; SURVIVAL RATE; THROMBOCYTOPENIA; TUMOR BIOPSY; VOMITING; WHEEZING;

EID: 0038461095     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(03)00319-8     Document Type: Conference Paper

References (21)

1. Group Chemotherapy in non-small cell lung cancer. a meta-analysis using updated data on individual patients from 52 randomised clinical trials Br. Med. J. 311:1995;899-909.
2. Dillman R.O., Herndon J., Seagren S.L., Eaton W.L. Jr., Green M.R. Improved survival in stage III non-small-cell lung cancer. seven-year follow-up of cancer and leukemia group B (CALGB) 8433 trial J. Natl. Cancer Inst. 88:1996;1210-1215.
3. Roth J.A., Fossella F., Komaki R.et al. A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer. J. Natl. Cancer Inst. 86:1994;673-680.
4. Rosell R., Gomez-Codina J., Camps C.et al. A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer. N. Engl. J. Med. 330:1994;153-158.
5. Roth J.A., Atkinson E.N., Fossella F.et al. Long-term follow-up of patients enrolled in a randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer. Lung Cancer. 21:1998;1-6.
6. Rosell R., Gomez-Codina J., Camps C.et al. Preresectional chemotherapy in stage IIIA non-small-cell lung cancer. a 7-year assessment of a randomized controlled trial Lung Cancer. 26:1999;7-14.
7. Depierre A., Milleron B., Moro-Sibilot D.et al. Preoperative chemotherapy followed by surgery compared with primary surgery in resectable stage I (except T1N0), II, and IIIa non-small-cell lung cancer. J. Clin. Oncol. 20:2002;247-253.
8. Giaccone G., Huizing M., Postmus P.E.et al. Dose-finding and sequencing study of paclitaxel and carboplatin in non-small cell lung cancer. Semin. Oncol. 22(Suppl. 9):1995;78-82.
9. Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin. Trials. 10:1989;1-10.
10. Kaplan E.L., Meier P. Non-parametric estimation from incomplete observations. J. Am. Stat. Assoc. 53:1958;457-481.
11. Calvert A.H., Newell D.R., Gumbrell L.A.et al. Carboplatin dosage. prospective evaluation of a simple formula based on renal function J. Clin. Oncol. 7:1989;1748-1756.
12. Cockcroft D.W., Gault M.H. Prediction of creatinine clearance from serum creatinine. Nephron. 16:1976;31-41.
13. Bonomi P., Kim K., Fairclough D.et al. Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin. results of an Eastern Cooperative Oncology Group trial J. Clin. Oncol. 18:2000;623-631.
14. Giaccone G., Splinter T.A., Debruyne C.et al. Randomized study of paclitaxel-cisplatin versus cisplatin-teniposide in patients with advanced non-small-cell lung cancer. The European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group. J. Clin. Oncol. 16:1998;2133-2141.
15. Kelly K., Crowley J., Bunn P.A. Jr.et al. Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer. a Southwest Oncology Group trial J. Clin. Oncol. 19:2001;3210-3218.
16. Ramsey S., Moinpour C., Lovato L., Grevstad P., Kelly K., Presant C. An economic analysis of Southwest Oncology Group Trial S9509. cisplatin/vinorelbine vs. carboplatin/paclitaxel for advanced nonsmall cell lung cancer Proc. Am. Soc. Clin. Oncol. 489a:2000;. (abstr 1913).
17. Schiller J.H., Harrington D., Belani C.P.et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N. Engl. J. Med. 346:2002;92-98.
18. Pisters K.M., Ginsberg R.J., Giroux D.J.et al. Induction chemotherapy before surgery for early-stage lung cancer. a novel approach. Bimodality Lung Oncology Team J. Thorac. Cardiovasc. Surg. 119:2000;429-439.
19. Siegenthaler M.P., Pisters K.M., Merriman K.W.et al. Preoperative chemotherapy for lung cancer does not increase surgical morbidity. Ann. Thorac. Surg. 71:2001;1105-1111.
20. Roberts J.R., Eustis C., Devore R., Carbone D., Choy H., Johnson D. Induction chemotherapy increases perioperative complications in patients undergoing resection for non-small cell lung cancer. Ann. Thorac. Surg. 72:2001;885-888.
21. Van Zandwijk N., Smit E.F., Kramer G.W.et al. Gemcitabine and cisplatin as induction regimen for patients with biopsy-proven stage IIIA N2 non-small-cell lung cancer. a phase II study of the European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group (EORTC 08955) J. Clin. Oncol. 18:2000;2658-2664.